Disease · MONDO_0003060
biliary tract cancer
6 sourcesdiseases-2026-09-18-0.1.0
Download JSON
Cite this record
ConductScience Library. biliary tract cancer. Diseases, record MONDO_0003060. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0003060
On this page
Disease
Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.
- Other names
- biliary tree cancer, cancer of biliary tree, malignant biliary tree neoplasm, malignant neoplasm of biliary tree, malignant tumor of biliary tract
- Open Targets
Drugs150
The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
| Drug | ChEMBL ID | Type | Open Targets' stage | Stage reported by | Reports | Of them trials | Trials shown here | Source |
|---|---|---|---|---|---|---|---|---|
| PEMIGATINIB | CHEMBL4297522 | Small molecule | Approval | PMDA | 2 | 1 | 1 | Drugs and targets |
| E-7090 | CHEMBL3686884 | Small molecule | Approval | PMDA | 1 | 0 | 0 | Drugs and targets |
| FUTIBATINIB | CHEMBL3701238 | Small molecule | Approval | PMDA | 1 | 0 | 0 | Drugs and targets |
| GEMCITABINE | CHEMBL888 | Small molecule | Phase 3 | ClinicalTrials.gov | 114 | 114 | 114 | Drugs and targets |
| CISPLATIN | CHEMBL11359 | Small molecule | Phase 3 | ClinicalTrials.gov | 74 | 74 | 74 | Drugs and targets |
| OXALIPLATIN | CHEMBL414804 | Small molecule | Phase 3 | ClinicalTrials.gov | 55 | 55 | 54 | Drugs and targets |
| CAPECITABINE | CHEMBL1773 | Small molecule | Phase 3 | ClinicalTrials.gov | 34 | 34 | 34 | Drugs and targets |
| FLUOROURACIL | CHEMBL185 | Small molecule | Phase 3 | ClinicalTrials.gov | 32 | 32 | 30 | Drugs and targets |
| DURVALUMAB | CHEMBL3301587 | Antibody | Phase 3 | ClinicalTrials.gov | 31 | 30 | 30 | Drugs and targets |
| PEMBROLIZUMAB | CHEMBL3137343 | Antibody | Phase 3 | ClinicalTrials.gov | 26 | 26 | 26 | Drugs and targets |
1 to 10 of 150
See all 150 drugsTargets98
The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.
| Target | Protein | Its drugs that act on it | Mechanisms | Highest stage of those drugs | Gene in Genes | Source |
|---|---|---|---|---|---|---|
| ERBB2 | Receptor tyrosine-protein kinase erbB-2 | 13 | Receptor protein-tyrosine kinase erbB-2 binding agent; Receptor protein-tyrosine kinase erbB-2 inhibitor; Receptor tyrosine-protein kinase erbB-2 binding agent | Phase 3 | https://conductscience.org/library/genes/2064 | Drugs and targets |
| PDCD1 | Programmed cell death protein 1 | 12 | Programmed cell death protein 1 antagonist; Programmed cell death protein 1 inhibitor | Phase 3 | https://conductscience.org/library/genes/5133 | Drugs and targets |
| CD274 | Programmed cell death 1 ligand 1 | 10 | Programmed cell death 1 ligand 1 binding agent; Programmed cell death 1 ligand 1 inhibitor; Programmed cell death 1 ligand 1 other | Phase 3 | https://conductscience.org/library/genes/29126 | Drugs and targets |
| KDR | Vascular endothelial growth factor receptor | 10 | Vascular endothelial growth factor receptor 2 inhibitor; Vascular endothelial growth factor receptor inhibitor | Phase 2/3 | https://conductscience.org/library/genes/3791 | Drugs and targets |
| EGFR | Epidermal growth factor receptor | 9 | Epidermal growth factor receptor erbB1 inhibitor | Phase 2/3 | https://conductscience.org/library/genes/1956 | Drugs and targets |
| FLT4 | Vascular endothelial growth factor receptor | 8 | Vascular endothelial growth factor receptor 3 inhibitor; Vascular endothelial growth factor receptor inhibitor | Phase 2/3 | https://conductscience.org/library/genes/2324 | Drugs and targets |
| FLT1 | Vascular endothelial growth factor receptor | 7 | Vascular endothelial growth factor receptor inhibitor | Phase 2/3 | https://conductscience.org/library/genes/2321 | Drugs and targets |
| KIT | Mast/stem cell growth factor receptor Kit | 6 | Stem cell growth factor receptor inhibitor | Phase 2/3 | https://conductscience.org/library/genes/3815 | Drugs and targets |
| PDGFRB | Platelet-derived growth factor receptor | 6 | Platelet-derived growth factor receptor beta inhibitor; Platelet-derived growth factor receptor inhibitor | Phase 2/3 | https://conductscience.org/library/genes/5159 | Drugs and targets |
| FGFR1 | Fibroblast growth factor receptor | 5 | Fibroblast growth factor receptor 1 inhibitor; Fibroblast growth factor receptor inhibitor | Approval | https://conductscience.org/library/genes/2260 | Drugs and targets |
1 to 10 of 98
See all 98 targetsTrials293
Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 2 more are not shown, since the checks do not confirm them.
| Trial | Title | Phase | Participants | Results first posted | Conditions | Drugs | Linked by | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04003636 | Pembrolizumab (MK-3475) Plus Gemcitabine/Cisplatin Versus Placebo Plus Gemcitabine/Cisplatin for First-Line Advanced and/or Unresectable Biliary Tract Carcinoma (BTC) (MK-3475-966/KEYNOTE-966) | Phase 3 | 1,069 | 2023-12-22 | Biliary Tract Carcinoma | CISPLATIN, GEMCITABINE, PEMBROLIZUMAB | Open Targets' reading of its record | ClinicalTrials.gov |
| NCT03875235 | Durvalumab or Placebo in Combination With Gemcitabine/Cisplatin in Patients With 1st Line Advanced Biliary Tract Cancer (TOPAZ-1) | Phase 3 | 810 | 2023-04-13 | Biliary Tract Neoplasms | DURVALUMAB | Its record names the disease | ClinicalTrials.gov |
| NCT04163900 | Comparing NUC-1031 Plus Cisplatin to Gemcitabine Plus Cisplatin in Patients With Advanced Biliary Tract Cancer | Phase 3 | 773 | 2023-05-24 | Biliary Tract Cancer | CISPLATIN, FOSGEMCITABINE PALABENAMIDE, GEMCITABINE | Its record names the disease | ClinicalTrials.gov |
| NCT03797326 | Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) in Previously Treated Participants With Select Solid Tumors (MK-7902-005/E7080-G000-224/LEAP-005) | Phase 2 | 611 | 2025-11-17 | Advanced Solid Tumors, Triple Negative Breast Cancer, Ovarian Cancer, Gastric Cancer, Colorectal Cancer, Glioblastoma, Biliary Tract Cancers, Pancreatic Cancer | LENVATINIB, PEMBROLIZUMAB | Open Targets' reading of its record | ClinicalTrials.gov |
| NCT02711553 | A Study of Ramucirumab (LY3009806) or Merestinib (LY2801653) in Advanced or Metastatic Biliary Tract Cancer | Phase 2 | 309 | 2021-02-26 | Biliary Tract Cancer, Metastatic Cancer, Advanced Cancer | MERESTINIB, RAMUCIRUMAB | Its record names the disease | ClinicalTrials.gov |
| NCT04066491 | Gemcitabine Plus Cisplatin With or Without Bintrafusp Alfa (M7824) in Participants With 1L BTC | Phase 2/3 | 309 | 2022-06-13 | Biliary Tract Cancer, Cholangiocarcinoma, Gallbladder Cancer | BINTRAFUSP ALFA, CISPLATIN, GEMCITABINE | Its record names the disease | ClinicalTrials.gov |
| NCT02564900 | Study of DS-8201a in Subjects With Advanced Solid Malignant Tumors | Phase 1 | 292 | 2021-06-23 | Advanced Solid Tumors | TRASTUZUMAB DERUXTECAN | Its record names the disease | ClinicalTrials.gov |
| NCT04579380 | Basket Study of Tucatinib and Trastuzumab in Solid Tumors With HER2 Alterations | Phase 2 | 217 | 2024-11-13 | Uterine Neoplasms, Uterine Cervical Neoplasms, Biliary Tract Neoplasms, Urologic Neoplasms, Carcinoma, Non-Small-Cell Lung, HER2 Mutations Breast Neoplasms | FULVESTRANT, TRASTUZUMAB, TUCATINIB | Its record names the disease | ClinicalTrials.gov |
| NCT02034110 | Efficacy and Safety of the Combination Therapy of Dabrafenib and Trametinib in Subjects With BRAF V600E- Mutated Rare Cancers | Phase 2 | 206 | 2023-08-21 | Cancer | DABRAFENIB, TRAMETINIB | Its record names the disease | ClinicalTrials.gov |
| NCT02443324 | A Study of Ramucirumab Plus Pembrolizumab in Participants With Gastric or GEJ Adenocarcinoma, NSCLC, Transitional Cell Carcinoma of the Urothelium, or Biliary Tract Cancer | Phase 1 | 175 | 2024-07-31 | Gastric Adenocarcinoma, Adenocarcinoma of the Gastroesophageal Junction, Non-small Cell Lung Cancer, Carcinoma, Transitional Cell, Biliary Tract Cancer | PEMBROLIZUMAB, RAMUCIRUMAB | Its record names the disease | ClinicalTrials.gov |
1 to 10 of 293
See all 293 trialsComparisons in its trials34
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Arm A (Pembrolizumab+Gemcitabine+Cisplatin) vs Arm B (Placebo+Gemcitabine+Cisplatin): Number of Participants Who Discontinued Study Intervention Due to an Adverse Event (AE) | 138 of 529 | 122 of 534 | 1,063 | NCT04003636 | Trial comparisons |
| Arm A (Pembrolizumab+Gemcitabine+Cisplatin) vs Arm B (Placebo+Gemcitabine+Cisplatin): Number of Participants Who Experience One or More Adverse Events (AE) | 524 of 529 | 532 of 534 | 1,063 | NCT04003636 | Trial comparisons |
| A - NUC-1031 and Cisplatin vs B - Gemcitabine and Cisplatin: deaths from any cause | 188 of 388 | 135 of 385 | 773 | NCT04163900 | Trial comparisons |
| A - NUC-1031 and Cisplatin vs B - Gemcitabine and Cisplatin: serious adverse events | 175 of 383 | 126 of 378 | 761 | NCT04163900 | Trial comparisons |
| Durvalumab + Gemcitabine + Cisplatin vs Placebo + Gemcitabine + Cisplatin: deaths from any cause | 308 of 341 | 326 of 344 | 685 | NCT03875235 | Trial comparisons |
| Durvalumab + Gemcitabine + Cisplatin vs Placebo + Gemcitabine + Cisplatin: serious adverse events | 168 of 338 | 152 of 342 | 680 | NCT03875235 | Trial comparisons |
| A - NUC-1031 and Cisplatin vs B - Gemcitabine and Cisplatin: Objective Response Rate (ORR) | 53 of 284 | 34 of 275 | 559 | NCT04163900 | Trial comparisons |
| Arm B: Atezo+PBO+CisGem (Cycle*1-8), Followed by Atezo+PBO (Cycle*9 and Beyond) vs Arm A: Atezo+Bev+CisGem (Cycle*1-8), Followed by Atezo+Bev (Cycle*9 and Beyond): deaths from any cause | 51 of 83 | 49 of 79 | 162 | NCT04677504 | Trial comparisons |
| Arm B: Atezo+PBO+CisGem (Cycle*1-8), Followed by Atezo+PBO (Cycle*9 and Beyond) vs Arm A: Atezo+Bev+CisGem (Cycle*1-8), Followed by Atezo+Bev (Cycle*9 and Beyond): serious adverse events | 43 of 81 | 36 of 78 | 159 | NCT04677504 | Trial comparisons |
| Pembrolizumab + Chemotherapy First Course vs Placebo + Chemotherapy First Course: deaths from any cause | 49 of 75 | 63 of 83 | 158 | NCT04924062 | Trial comparisons |
1 to 10 of 34
See all 34 comparisons in its trialsPapers from its trials211
The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Data dates
The date of each source this release read.
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this disease from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0003060
GET https://conductscience.org/api/diseases/v1/MONDO_0003060/drugs?page=2